

Andre Larente speaks to Mario Drolet about the importance of the DIAGNOS agreement with IRIS

In a recent InvestorIntel interview, Mario Drolet speaks with André Larente, President of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) about Diagnos' multi-year agreement with IRIS, a New Look Vision Group Inc. company, to implement Artificial Intelligence technology with support from the INVEST-AI Program.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Mr. Larente highlighted the strategic importance of the agreement as it creates a new market for Diagnos in form of optometry stores. With 406 locations operating across North America, New Look Vision is a market leader in eye care products and services and the agreement represents a major breakthrough for continued global commercialization of Diagnos' technology.

To watch the full interview, click here.

About DIAGNOS:

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following

regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

To learn more about Diagnos Inc., [click here](#)

Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this

interview, please email info@investorintel.com.

Diagnos' André Larente on Entering the DACH and Central European Healthcare Market

In a recent InvestorIntel interview, Tracy Weslosky spoke with André Larente President of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) about Diagnos' distribution agreement to enter the healthcare market in both DACH and Central European countries.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Mr. Larente went on to say that the region is a very large market as a large majority of patients suffer from diabetes and hypertension. He also provided an update on a successful Proof-of-Concept pilot study of its stroke predictor (CARA-ST) based on images of the retina. He said that with a 99% success rate, the pilot study was very successful in identifying people at an early stage of being at risk of having a stroke.

To watch the full interview, [click here](#).

About Diagnos Inc.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and

easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

To learn more about Diagnos Inc., [click here](#)

Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on www.sedar.com and to carry out

independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.